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Abstract: The metabolites produced by the host’s gut microbiota have an important role in the
maintenance of intestinal homeostasis, but can also act as toxins and induce DNA damage in colorectal
epithelial cells increasing the colorectal cancer (CRC) chance. In this scenario, the impact of some of the
components of the natural human gastrointestinal microbiota, such as Enterococcus faecalis (E. faecalis),
at the onset of CRC progression remains controversial. Since under dysbiotic conditions it could
turn into a pathogen, the aim of this study was to compare the effect of E. faecalis’ strains (isolated
from CRC patients and healthy subjects’ stools) on the proliferation of different colorectal cells lines.
First, we isolated and genotyping characterized the Enterococcus faecalis’ strains. Then, we analyzed
the proliferation index (by 3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide (MTT)
assay) of three tumor and one normal intestinal cell lines, previously exposed to E. faecalis strains
pre-cultured medium. Stool samples of CRC patients demonstrated a reduced frequency of E. faecalis
compared to healthy subjects. In addition, the secreted metabolites of E. faecalis’ strains, isolated from
healthy donors, decreased the human ileocecal adenocarcinoma cell line HCT-8 and human colon
carcinoma cell line HCT-116 cell proliferation without effects on human colorectal adenocarcinoma
cell line SW620 and on normal human diploid cell line CLR-1790. Notably, the metabolites of the
strains isolated from CRC patients did not influence the cell growth of CRC cell lines. Our results
demonstrated a new point of view in the investigation of E. faecalis’ role in CRC development,
which raises awareness of the importance of not only associating the presence/absence of a unique
microorganism, but also in defining the specific characteristics of the different investigated strains.
Keywords: colorectal cancer; Enterococcus faecalis; bacterial metabolites; gut microbiota; tumor
cell lines
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1. Introduction
Colorectal cancer (CRC) is one of the most commonly diagnosed cancers among both men and
women worldwide, being the third most frequent in many high-income countries, with an estimated
more than 100,000 new cases expected in 2018 [1]. The CRC incidence in low-income countries is
closely related with differences in lifestyle [2,3], with only 15% of cases having a familial feature,
whereas sporadic forms represent 85% [4]. Environmental factors, such as smoking, alcoholism,
obesity, sedentary lifestyle, consumption of red meat, high-fat diet, and inadequate fiber intake,
are closely involved in the CRC onset and progression [5]. All these risk factors also have a modulating
role on the host gut microbiota (GM) composition, whose effects on CRC progression/protection
have been investigated during the last years [6,7]. The gut microbiota, a natural defensive barrier to
infections, is involved in several physiological functions and plays a key role in maintaining the gut
homeostasis [8]. The GM members can modulate the mucosal immune system, as well as directly
change the expression of some host genes associated with nutrient uptake, metabolism, angiogenesis,
and mucosal barrier functions [9,10].
The GM’s protective role against intestinal diseases is closely linked with its ability to ferment
a range of dietary substances that are not completely digested and absorbed in the small intestine.
The microbial carbohydrate fermentation, for example, produces short chain fatty acids (SCFAs),
such as acetic, propionic, and butyric, which can be further metabolized by mammalian cells for energy,
thus having beneficial effects. On the other hand, bacterial transformation of dietary components and
other chemicals in the intestinal lumen is associated with the production of carcinogenic agents, whose
damaging effects on colonic mucosal cells can influence cancer development [11]. In fact, approximately
20% of cancers are associated with microbes [10], especially CRC [12–14], where a dynamic crosstalk
exists between intestinal epithelial cells, the microbes (that colonize their apical surface), and the
surrounding local immune cells [15], which, in turn, have a key role in CRC progression, especially
T cells [16].
While some GM members (Streptococcus bovis, Bacteroides, Clostridia, and Helicobacter pylori) have
an evident role on cancer promotion [17] and others play protective roles (Lactobacillus spp. and
Bifidobacterium spp.) [18], for the symbiotic lactic acid bacteria (LAB), Enterococcus faecalis (E. faecalis),
a controversial role in CRC has been hypothesized. This Firmicutes phylum member belonging to
the Enterococcaceae family, even if used as a probiotic product [19,20] due to its great ability to confer
beneficial effects on human health by their fermented products [21], has also been regarded as being
possibly involved in CRC development, given its ability to damage the deoxyribonucleic acid (DNA)
of colonic epithelial cells [22]. Moreover, previous studies have demonstrated that the feces of CRC
patients showed increased concentrations of E. faecalis, strengthening its role as cancer promoter [23,24].
Among intestinal Enterococci, E. faecalis is the most prevalent cultured species found in human
feces (105 to 107 Colony Forming Unit (CFU)/g), followed by E. faecium (104 to 105 CFU/g), but these
proportions change with the host’s geographical location and especially with diet [25]. E. faecalis is one
of the first colonizers of the human gastrointestinal tract and it has a major impact on intestinal immune
development in the very early life stages [26]. In newborns, it plays a protective role, regulating the
colonic homeostasis during development by suppressing pathogen-mediated inflammatory responses
in human intestinal epithelial cells, inducing interleukin (IL)-10 expression [27] and attenuating
proinflammatory cytokine secretions, especially IL-8 [28].
Aiming to verify whether E. faecalis strains isolated from CRC patients’ feces have substantial
differences with those isolated from healthy donors’ samples, we recruited nine CRC Italian patients
and nine healthy donors matched by age. Our results pointed out significant genotyping differences
among all the E. faecalis strains, mainly regarding the genes of adhesion and virulence factors.
Consequently, we analyzed the effect of the metabolites of the different isolated strains on three
CRC cell lines’ proliferation (and a normal colon cell line), demonstrating an antiproliferative role only
for those strains isolated from healthy donors.
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2. Material and Methods
2.1. Ethical Statement
The Local Ethics Committee (Prot. 2010/0012462) approved the study. Institutional Ethics
Committee Statement: All procedures involving the cells of healthy donors were done according
to the Declaration of Helsinki and approved by the local Ethics Committee by the AOUC Careggi
Institutional Review Board (Prot. 2010/0012462).
2.2. CRC Patients and Healthy Donors
Overall, nine patients with CRC and nine healthy donors were enrolled at Careggi University
Hospital (Florence, Italy) (Table 1) between April and May 2016. Exclusion criteria included antibiotic
intake and use of probiotics/culture milk 2 months before and within the study. All the participants
provided an informed written consent prior to enrolment, in compliance with national legislation and
the Code of Ethical Principles for Medical Research Involving Human Subjects of the World Medical
Association (Declaration of Helsinki).
Table 1. CRC patient and healthy donors’ characteristics.
Donors
(Healthy—HD Colon
Cancer—CC)
Age/Gender
(♀/♂) Histotype/Stage
HD01 57 ♀ n/a
HD02 60 ♂ n/a
HD03 56 ♂ n/a
HD04 53 ♀ n/a
HD05 68 ♀ n/a
HD06 65 ♂ n/a
HD07 68 ♀ n/a
HD08 48 ♂ n/a
HD09 52 ♂ n/a
CC01 78 ♂ Colorectal adenocarcinoma with moderatedifferentiation (pT3N0)
CC02 79 ♂ Colorectal adenocarcinoma with moderatedifferentiation (pT3N0)
CC03 68 ♀ Colorectal adenocarcinoma with moderatedifferentiation (pT2N0)
CC04 78 ♂ Colon intramucosal adenocarcinoma (pT2N0)
CC05 40 ♂ Colorectal adenocarcinoma with moderatedifferentiation (pT3aN1aMx)
CC06 78 ♂ Colorectal adenocarcinoma with moderatedifferentiation (pT1N0)
CC07 81 ♀ Colorectal adenocarcinoma with moderatedifferentiation (pT2N0Mx)
CC08 62 ♂ Colorectal adenocarcinoma with moderatedifferentiation (pT2N0Mx)
CC09 63 ♂ Colorectal adenocarcinoma with moderatedifferentiation (pT3N0Mx)
CRC: colorectal cancer; ♀: female; ♂: male; n/a: not available.
2.3. Isolation and Genotyping of Enterococcus faecalis
To isolate the E. faecalis strains, we resuspended 0.25 g of feces in 250 µL of sterile saline (NaCl
0.9%). From this solution, we plated 50 µL onto Columbia CNA (colistin, nalidixic acid) blood agar
with crystal violet (CV) (CNA-CV Agar) with 5% sheep blood (Sh) enrichment (CNA-CVSh) (Becton,
Dickinson and Company, Franklin Lakes, NJ, USA) and incubated it at 37 ◦C for 30 h. Then, we isolated
single colonies (±0.032 CFU/mg of stool) and cultivated them onto Columbia with 5%sheep blood
J. Clin. Med. 2019, 8, 388 4 of 15
(COS) medium (Biomerieux, Grassina, FI, Italy) for 24 h at 37 ◦C. To identify the species’ level of
putative Enterococci colonies, we performed a Matrix Assisted Laser Desorption/Ionization Time of
Flight MALDI-TOF assay (Vitek MS, BioMérieux Inc., Marcy l’Etoile, France). The confirmed E. faecalis
colonies were stored at −80 ◦C in brain heart infusion broth medium (BHI) (Oxoid, Altrincham,
Cheshire, UK) with 10% glycerol added. When necessary, we grew these strains on COS medium at
37 ◦C for 24 h before performing different experiments.
To evaluate the clonal diversity of the isolated E. faecalis colonies (n = 16), we performed a Random
Amplified Polymorphic DNA- Polymerase Chain Reaction (RAPD)-PCR assay, as previously described
by Martin et al. 2005 [29]. RAPD-PCR was performed on cell lysates obtained by resuspension of
single bacterial colonies in 300 µL of Tris- Ethylenediaminetetraacetic acid (TE) buffer, incubation for
15 min 95 ◦C, and clarification through centrifugation for 5 min at 13,000 rpm.
Quantitative detection of E. faecalis was performed by q-PCR on total DNA extracted from subjects’
feces using the DNeasy Power Lyzer Power Soil DNA isolation Kit (MoBio-QIAgen, Valencia, CA,
USA). We used a species-specific primer set for the detection of E. faecalis and universal primers for
the detection of the total bacterial loads to target the 16S rRNA gene, as previously described by
Sedgley et al. [30]. The PCR thermal conditions were: 3 min for the initial enzyme activation/DNA
denaturing step at 95 ◦C followed by 44 consecutive cycles at 95 ◦C for 20 s; (57 ◦C E16S) (53 ◦C for
U16S) for 45 s; 60 ◦C for 5 s.
As previously described, whole genome sequencing was performed [31] on selected E. faecalis
to include all the different clonal profiles, identified according to RAPD-PCR results (n = 8).
We investigated the clonal relatedness by the determination of: (i) The Multilocus sequence typing
(MLST) profile through the MLST 1.8 tool [32] using the assembled whole genome sequences as the
input; (ii) the core genome SNP phylogeny, through the CSI Phylogeny 1.4 tool [33], using default
parameters and the raw sequence reads as the input. We generated the phylogenetic trees, using the
E. faecalis ATCC® 29212™ genome (GenBank acc. no. NZ_CP008816.1) as a reference. Identification of
prophage sequences was carried out using PHAge Search Tool Enhanced Release (PHASTER) [34]. The
presence of virulence factors and antibiotic resistance genes was assessed using the VirulenceFinder
1.5 and the ResFinder 3.0 tools [35], respectively. We performed the sequence comparison by using
the Basic Local Alignment Search Tool (BLASTN) software and the nr or wgs databases [36]. Draft
genomes of sequenced strains were deposited at National Center for Biotechnology Information (NCBI)
as Whole Genome Sequence WGS projects (accession numbers to be assigned).
2.4. Secreted Metabolites
To obtain pre-fermented medium, we used the protocol previously described by Grootaert et al. [37]
with some modifications. Briefly, the E. faecalis strains were cultivated in 5 mL of BHI medium at 37
◦C. After 10 h, an equal number of cells (3 × 108 CFU/mL) was centrifuged (5 min, 13,000 rpm) and
washed with 1 mL of PBS. The pellets were suspended in 5 mL of Roswell Park Memorial Institute
(RPMI) 1640 medium (Thermo Fisher Scientific Inc., Waltham, MA, USA) without antibiotics or fetal
bovine serum (FBS) and incubated at 37 ◦C for 3 h. Thereafter, the suspension was centrifuged (5 min,
4000 rcf) and the supernatant was sterilized with a 0.22 mm filter (Millipore, Billerica, MA, USA) and
retained as the pre-fermented medium. We used the commercial ATCC29212 strain as a control (ATCC,
Manassas, VA, USA).
2.5. Gas Chromatography Mass Spectrometry (GC-MS) Analysis of SCFAs
Methanol and tert-butyl methyl ether (Chromasolv grade), sodium bicarbonate and hydrochloric
acid (reagent grade), (2H3)Acetic, (2H3)Propionic, (2H7)iso-Butyric and (2H9)iso-Valeric (used as
internal standards (ISTDs)), acetic acid, propionic acid, butyric acid, isobutyric acid, valeric acid, and
isovaleric acid (analytical standards grade) were purchased by Sigma-Aldrich (Milan, Italy). MilliQ
water 18 MΩ was obtained from Millipore’s Simplicity system (Milan, Italy). The SCFAs’ analysis was
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performed by an Agilent GC-MS system composed with a 5971 single quadrupole mass spectrometer,
5890 gas-chromatograph, and 7673 autosampler.
The SCFAs in the samples (Table S2) were analyzed as free acid form using a SupelcoNukol
column, with a 30 m length, 0.25 mm internal diameter, and 0.25 µm of film thickness with the
temperatures program as follows: Initial temperature of 40 ◦C was held for 1 min, then it was increased
to 150 ◦C at 30 ◦C/min, and finally increased to 220 ◦C at 20 ◦C/min. 1 µL aliquot of the extracted
sample was injected in splitless mode (splitless time 1 min) at 250 ◦C, while the transfer line temperature
was 280 ◦C. The carrier flow rate was maintained at 1 mL/min.
2.6. Cell Lines
The used cell lines were purchased from the American Type Culture Collection (ATCC, Manassas,
VA, USA). Since primary and metastatic tumor cells have different metabolic, genetic, epigenetic,
and morphological characteristics, we decided that it was more appropriate to evaluate the effect
of E. faecalis metabolites in different CRC cell lines. In detail, we chose HCT-116 and HCT-8 as the
primary tumors’ model and SW-620 as a lymphonode metastasis model. The embryo colonic cell line,
CLR-1790, was used as the non-tumor control. The culture conditions of each cell line are reported in
Table 2.
Table 2. Cell lines’ features and culture conditions.
Cell Line Medium Other Information
HCT-116
DMEM + 2 mM L-Glutamine + 100 U/mL
Penicillin + 100 µg/mL Streptomycin + 10%
FBS
(CCL-247™) ATCC®, Manassas, VA, USA.
Colon; colorectal carcinoma, male,
epithelial, primary tumor.
HCT-8
DMEM + 2 mM L-Glutamine + 100 U/mL
Penicillin + 100 µg/mL Streptomycin +
10% FBS
(CCL-244™) ATCC®, Manassas, VA, USA.
Colon; ileocecal colorectal adenocarcinoma;
primary tumor, epithelial.
SW-620
DMEM + 2 mM L-Glutamine + 100 U/mL
Penicillin + 100 µg/mL Streptomycin +
10% FBS
(CCL-227™) ATCC®, Manassas, VA, USA.
Colon; derived from metastatic site: lymph
node; Dukes’ type C, colorectal
adenocarcinoma; male; epithelial
CLR-1790
50% DMEM + 50% Ham’s F12 Nutrient Mixture
+ 2 mM L-Glutamine + 100 U/mL Penicillin +
100 µg/mL Streptomycin + 10% FBS
(CCD 841 CoN) ATCC®, Manassas, VA,
USA. Colon; normal; 21 weeks gestation
fetus; epithelial.
HCT-8: Human ileocecal adenocarcinoma cell line; HCT-116: Human colon carcinoma cell line; SW-620:human
colorectal adenocarcinoma cell line; CLR-1790: normal human diploid cell line; DMEM: Dulbecco’s Modified Eagle
Medium; FBS: Fetal Bovine Serum.
2.7. Treatment of Cell Lines with Pre-Fermented Medium and MTT Assay
The human HCT-116, HCT-8, and SW-620 colon cancer cells, and the normal intestinal CLR-1790
cells were plated on flat-bottomed 96-well culture plates (5 × 103 cells/well) and incubated with their
respective culture medium for 24 h at 37 ◦C under 5% CO2 tension. After, we added the pre-fermented
medium in a proportion of 1:5 (pre-fermented medium:culture medium). We used RPMI as the control.
The effect of the E. faecalis secreted metabolites on cell proliferation was determined using the MTT
assay [38] after 72 h of culture. Absorbance was measured at 595 nm using the iMark microplate reader
(Biorad, Hercules, CA, USA) for the cell viability calculation while the absorbance of the controls was
set as 100% of cell viability (% of cell viability = (sample O.D./control O.D.) × 100). Analyses were
performed in three independent experiments, with four experimental replicates for each experimental
point (% of cell viability = (sample absorbance/control absorbance) × 100).
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2.8. Ki67 Immunofluorescence Analysis
Cells were grown on glass coverslips, washed twice with 1 mL of cold PBS, and fixed for 20 min
in 3.7% paraformaldehyde in PBS and permeabilized with 0.3% Triton X-100 in PBS for 5 min. Cells
were incubated in blocking buffer (5% FBS and 0.3% Triton X-100 in PBS) for 1 h at room temperature.
Then, the cells were incubated overnight at 4 ◦C with ki67 antibody (Santa Cruz Biotechnology, Dallas,
TX, USA) and successively for 1 h with the anti-mouse DyLightTM 488 secondary antibody (KPL,
Gaithersburg, MD, USA) at room temperature. After staining of the nuclei with Hoechst 33242 dye
(4′,6-diamidino-2-phenylindole; Life Technologies, Carlsbad, CA, USA), the cells were dried, mounted
onto glass slides with ProLong Diamond AntifadeMountant (Thermo Fisher Scientific, Waltham, MA,
USA), and examined with a confocal microscopy using a Nikon Eclipse TE2000-U (Nikon, Tokyo,
Japan). A single composite image was obtained by superimposition of 6 optical sections for each
sample observed. The collected images were analyzed by ImageJ software [39]. All the experiments
have were repeated three times.
2.9. Statistical Analysis
Differences in the proliferation index for each experimental group, compared to the control one,
were assessed using analysis of variance (ANOVA). To avoid bias due to the variability between the
experiments, the factor defining the different experimental groups was crossed with a second factor
defining the different experiments (two-way ANOVA). p-values lower than 0.05 were considered
statistically significant. Figures are representative from all experiments that were realized during
the study.
3. Results
3.1. Decreased Frequency of E. faecalis on Stool of CRC Patients
The presence of E. faecalis was investigated in the feces of healthy donors (HD) and CRC patients
(CC) (Table 1) through two complementary approaches. Firstly, we performed the isolation of E. faecalis
from fresh stools, and we revealed its presence in four over nine HD, while only in two over nine CC.
In detail, we isolated 12 colonies from four healthy donors and four colonies from two CRC patients
(Table 3). MALDI-TOF analysis showed that five of the total 16 isolated colonies were not properly
classified, being identified as E. faecium or E. galinarium and were discarded. The remaining 11 colonies
were correctly identified as E. faecalis and were subjected to clonal analysis. Following the RAPD-PCR
assay, eight different clonal profiles were identified: Six (EFH01-EFH06) from the four healthy donors
and two from the two (CRC01 and CRC02) CC patients (Table 3).
In addition, to evaluate the overall prevalence of E. faecalis in the same subjects, including
non-culturable strains, we performed a q-PCR analysis using the total DNA extracted from ultra-freeze
stool samples (maximum two months of storage at −80 ◦C). E. faecalis’ presence was detected in seven
over nine healthy donors (HD01, HD02, HD03, HD05, HD06, HD07, HD09), and only in two over nine
CRC patients (CC6 and CC8). Taken together, the isolation and q-PCR approaches allowed us to detect
the presence of E. faecalis in the stools of 77% of healthy donors and in 22% of CRC patients.
3.2. Genotypic Characterization of E. faecalis’ Strains
The eight clonally different, representative, E. faecalis strains (Table 3) were genotyped by whole-
genome-sequencing. First, we detected a different content of virulence genes (Supplementary Materials
Table S1). Then, the clonal analysis by determination of the sequence type (ST) revealed that selected
strains were part of E. faecalis lineages previously found to be associated with: (i) Clinical isolates
(EFH04/ST209, EFH06/ST16, CRC01/ST40, and CRC02/ST59); (ii) the healthy gut (EFH01 and EFH05
both ST21); and (iii) sporadically detected or not characterized clones (EFH02/ST47 and EFH03)
(Table 3 and Figure 1). Subsequently, these eight strains were used to produce a pre-fermented
RPMI medium.
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Table 3. Isolated colonies of E. faecalis and characterized strains used for experimental protocols.
Donors E. faecalis/TotalEnterococci
E. faecalis Strains
Used ST
CRC patients
CC1 -/- -
CC2 -/- -
CC3 -/- -
CC4 -/- -
CC5 -/- -
CC6 2/3 CRC01 40
CC7 -/- -
CC8 2/2 CRC02 59
CC9 -/- -
Healthy donors
HD1 3/8 EFH01 21
HD2 4/10
EFH02 47
EFH05 21 *
EFH06 16
HD3 3/8 EFH03 unk
HD4 -/- -
HD5 -/4 -
HD6 2/5 EFH04 209
HD7 -/5 -
HD8 -/3 -
HD9 -/6 -
Total isolated strains 16/54 8
E. faecalis: Enterococcus faecalis; CC: Colon Cancer; HD: Healthy donors; EFH: Enterococcus faecalis healthy
ST: sequence type; * EFH01 and EFH05 are both classified as ST21, even if they display genotypic and
functional differences.J. Clin. Med. 2019, 8, x FOR PEER REVIEW 8 of 15 
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3.3. Characterization of Secreted SCFAs
Since LAB are known for their ability to produce SCFAs, we performed a quantitative analysis
of a pan l of SCFAs in pre-ferm nted medium samples obtained from all isolated E. faecalis strains
(T ble 4). As expected, ac tic acid was th most ignificant SCFA produced by ll strains, followed by
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iso-valeric acid. In addition, in all samples, we detected an SCFA not included in the panel of studied
compounds. Taking into the account the retention time, distnace to iso-valeric acid, its fragmentation
ions, and the relative abundances, we hypothesized the structure of 2-methyl-butyric acid. Since it is
not included in the calibrated SCFAs, a quantitative evaluation was carried out using the calibration
curve and reference ISTD of the iso-valeric acid. Data of the medium sample without fermentation of
the studied strains did not show the presence of SCFAs, proving that they were produced by bacterial
activities. Overall, we did not reveal substantial differences in the productions of SCFAs among all the
isolated strains.
Table 4. Quantitative analyses of SCFAs in pre-fermented medium samples.
Samples Acetic±SD (ug/mL)
Propionic
± SD
(ug/mL)
Butyric±
SD
(ug/mL)
Iso-Butyric
± SD
(ug/mL)
Iso-Valeric
± SD
(ug/mL)
2-MethylButyric
± SD
(ug/mL)
Valeric±
SD
(ug/mL)
RPMI n.q. n.q. n.q. n.q. n.q. n.q. n.q.
EFH01 393.5 ± 71.1 n.q. n.q. n.q. 4.7 ± 1.0 4.2 ± 0.8 n.q.
EFH02 268.7 ± 19.7 2.7 ± 2.5 4.2 ± 1.1 n.q. 3.3 ± 0.4 2.8 ± 0.2 0.3 ± 0.6
EFH03 379.7 ± 43.6 n.q 2.1 ± 1.8 n.q. 3.3 ± 0.5 3.3 ± 0.4 n.q.
EFH04 324.2 ± 23.9 n.q 1.0 ± 1.7 n.q. 4.8 ± 0.2 3.6 ± 0.2 n.q.
EFH05 394.1 ± 56.1 0.8 ± 1.4 1.0 ± 1.7 n.q. 4.6 ± 0.4 4.1 ± 0.4 n.q.
EFH06 381.2 ± 16.1 n.q. n.q. n.q. 6.4 ± 0.5 6.1 ± 0.6 n.q.
CRC01 417.5 ± 89.3 1.2 ± 2.1 2.6 ± 2.3 n.q. 4.2 ± 0.9 4.0 ± 0.8 n.q.
CRC02 399.7 ± 44.5 n.q. 3.3 ± 0.1 n.q. 3.7 ± 1.1 2.4 ± 0.4 n.q.
ATCC 380.6 ± 45.9 n.q. n.q. n.q. 4.7 ± 0.8 3.5 ± 0.6 n.q.
n.q.: below limit of detection of the quantitative method. Data are presented as mean ± SD (standard deviation).
SCFAs: Short chain fatty acids; RPMI: Roswell Park Memorial Institute medium.
3.4. From the Isolated Strains, Three were Able to Decrease Tumor Cell Growth
MTT assays were made at 24, 48, and 72 h of HCT-8, HCT-116, SW-620, and CRL-1790 cells’
exposure to the pre-fermented medium with E. faecalis strains. In the preliminary experiments,
we observed effects over the cell viability/proliferation after only 72 h, without differences regarding
the control after 24 and 48 h (data not shown). Therefore, all the following experiments were performed
at 72 h of pre-fermented medium exposure. The results revealed that secreted metabolites from the
strains EFH01, EFH02, EFH03, and EFH04 (all from healthy donors) reduced the viability/proliferation
of HCT-8 cells; similar results were also obtained with HCT-116 cells (except for EFH04), while no
effect resulted in the SW-620 cell line (Figure 2). Secreted metabolites from EFH05, EFH06, CRC01,
and CRC02 strains did not elicit any significant effects in the three CRC cell lines. Aiming to evaluate
the potential effect of strains’ metabolites on normal cells, we used the embryo colonic cell line,
CLR-1790. Noteworthy, we observed that E. faecalis strains’ metabolites did not significantly interfere
with the viability/proliferation of these cells.
To better clarify the extent to which E. faecalis secreted metabolites affect cell proliferation,
we employed Ki67 immunofluorescence staining as an accurate measurement of cellular proliferation
(Figure 3). We observed that the Ki67 expression was decreased only on HCT-8 and HCT-116 cell lines
cultured with the metabolites of the EFH01, EFH02, EFH03, and EFH04 strains, corroborating the
results of the MTT assays (Figure 4). Finally, in agreement with the MTT assay, a complementary cell
cycle phase distribution assay demonstrated a trend to decreasing G0/G1 and increasing S phases,
mainly with the metabolites of the EFH03 strain (Supplementary Materials, Figure S1).
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4. Discussion
In this study, aiming to investigate the potential role of E. faecalis in CRC development,
we compared the effect of E. faecalis strains isolated from CRC patients’ and healthy subjects’ stools on
the viability/proliferation of different colorectal cells lines. Actually, gut microbes can regulate the
colonic epithelial cells’ homeostasis (proliferation, differentiation, and apoptosis) and GM dysbiosis
has been widely associated with CRC development [12–14]. In addition, metagenome-wide association
studies on fecal samples have characterized numerous microbial markers of CRC [40,41]. Some authors
documented a higher abundance of E. faecalis in CRC tumor and adjacent tissue [42], as well as in stool
samples of CRCpatients [23,43], as compared to healthy subjects. However, in our cohort of patients,
we did not confirm these previous findings. In detail, only two out of the nine CRC patients had
cultivable E. faecalis in stool samples, while in healthy donors, we detected strains in seven out of the
nine donors. In former studies [24,44], the authors used only a PCR-based experimental approach that
did not unequivocally distinguish E. faecalis from other Enterococci. Conversely, we used a primer pair
with a higher specificity to evaluate the presence of E. faecalis. So, a direct comparison among our data
with previous ones is affected by this procedural bias. Although our observations were restricted to a
limited number of subjects, the remarkable differences disclosed between CRC patients and healthy
donors suggest that the majority of CRC patients possibly lose the physiological stool presence of
E. faecalis that we supposed to have a protective role on gut health.
In support of our hypothesis, recent studies demonstrated that E. faecalis can affect the
phosphorylation status of the peroxisome proliferator-activated receptor (PPAR)γ, triggering the
activation of its downstream pathways [27]. PPARγ acts as a growth-limiting and pro-differentiating
transcription factor in colonic epithelial cells [44] and contributes to innate antimicrobial immunity in
the colon [45]. Deregulation of the PPARγ axis in CRC progression has been described [44] and efforts
aimed to identify PPARγ agonists as anti-neoplastic agents are ongoing. Therefore, the disappearance
of E. faecalis might reduce (or remove) the presence of a PPARγ modulator, thus contributing to a
pro-tumoral milieu. It will be of interest to focus future studies on the definition of the precise phase of
E. faecalis disappearance in the feces, during CRC progression.
Aiming to understand whether genetic differences documented by whole-genome-sequencing
involve variation in the fermentation processes and their final products, we analyzed the concentrations
of SCFAs on the culture supernatant of all isolated E. faecalis strains. SCFAs are physiologically active
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products, primarily obtained by the fermentation of soluble dietary fiber and resistant starch by
commensal bacteria in the colon [46]. SCFAs can profoundly affect the inflammatory response [47,48],
being closely linked to decreased CRC incidence [49], and also the adaptive immune response [50]
(which has a key role in CRC progression, as we have previously demonstrated [16]). The in vitro
assay demonstrated that SCFAs are able to inhibit the proliferation [51] of CRC cell lines by inducing
their apoptosis [52]. The most frequent SCFAs in the colon and stool samples are acetic, propionic, and
butyric acids, which are present in an approximate molar ratio of 60:20:20 [53,54].
SCFAs, especially those mentioned, are one of the most important products of the fermentation
process and present diverse beneficial properties to human health, such as regulation of metabolism,
inflammation, and disease (reviewed by Tan et al.) [55]. We did not observe significant differences in
the SCFA concentrations among the isolated strains; however, the presence of 2-methyl-butyric acid,
which was produced by all strains, was interesting, since this volatile organic compound can be used
for discriminate analysis in the diagnosis of gastrointestinal diseases [56]. Therefore, its inclusion in
the SCFAs’ panel for future studies could improve the correlation between the analytical data and
biological evidence.
Bearing in mind the controversial role of E. faecalis in CRC development6 and the different
behaviour of CRC cell lines in response to external stimuli (as well as each tumor having its own
genotype, origin, and proliferative index [57]), we compared the effect of each isolated strain’s
fermented products on the proliferation of three tumor cell lines: HCT-8 and HCT-116 and SW620s. As a
result, we documented an antiproliferative effect of four (to note, all isolated from the healthy donors)
of the eight isolated strains on HCT-8 and HCT-116 cells, while the others (two from CRC patients
and two isolated from the HD02 subject) had no effect. In addition, we did not reveal any significant
anti-proliferative effects in SW-620 cells, a very important result, on normal colonic CRL-1790 cells.
Therefore, we disclosed a heterogeneous scenario, where only some E. faecalis strains derived from
healthy donors possess inhibitory effects on primitive tumor-derived CRC cells’ viability/proliferation.
Coherent with observation of a severe reduction of E. faecalis presence in the feces of CRC patients, the
isolated strains did not show any anti-tumoral effect.
The differential ability of the isolated strains to impact colon cancer cells’ viability/proliferation,
although perhaps not due to differences in SCFAs’ production, could depend on the production of
numerous other metabolites (that we aim to investigate in future studies). For example, the GM
products of various polyphenols’ metabolism (such as urolithins, benzoic acid, and 3-phenypropionic
acid) are capable of inhibiting the proliferation of different human colon cancer cell lines [58,59].
In addition, isothiocyanates, the hydrolysis products of glucosinolates of various bacterial species,
including E. faecalis [60], have been shown to have anti-carcinogenic properties in both in vivo and
in vitro studies, causing cell cycle arrest and inducing apoptosis [61].
Overall, the obtained results lay the groundwork for a more in-depth characterization of the
crosstalk between E. faecalis and CRC development, which is based not only on the evaluation of its
presence in feces, but also looks at the biology of each different strain.
In conclusion, we demonstrated, for the first time, that some E. faecalis strains may have
anti-tumoral properties and, in addition, different strains could have a highly heterogeneous content
of virulence factors [62,63] (Supplementary Materials). Therefore, in future investigations, we suggest
the specific lineages of E. faecalis are investigate to clarify their role in both healthy hosts and in
gut inflammation.
Finally, we suggest that E. faecalis strains with a probable protective role, such as EFH01,
EFH02, and EFH03, should be investigated in order to be used as a potential probiotic treatment
of pre-CRC intestinal disorders (e.g., inflammatory bowel disease (IBD) and adenoma) to prevent
disease progression.
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